(Q38116472)

29 August 2017

title

Abatacept: a review of its use in the management of rheumatoid arthritis (English)

1 reference

29 August 2017

1 reference

1

Gillian M Keating

1 reference

29 August 2017

publication date

1 July 2013

1 reference

29 August 2017

1 reference

29 August 2017

volume

73

1 reference

29 August 2017

issue

10

1 reference

29 August 2017

page(s)

1095-1119

1 reference

Canadian Rheumatology Association recommendations for pharmacological management of rheumatoid arthritis with traditional and biologic disease-modifying antirheumatic drugs

29 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0080-9

Biologic rheumatoid arthritis therapies: do we need more comparative effectiveness data?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0080-9

2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0080-9

Abatacept: a costimulatory inhibitor for treatment of rheumatoid arthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0080-9

CTLA4Ig: bridging the basic immunology with clinical application

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0080-9

2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0080-9

Abatacept, a novel CD80/86-CD28 T cell co-stimulation modulator, in the treatment of rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0080-9

The evolving clinical profile of abatacept (CTLA4-Ig): a novel co-stimulatory modulator for the treatment of rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0080-9

Abatacept Limits Breach of Self-Tolerance in a Murine Model of Arthritis via Effects on the Generation of T Follicular Helper Cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0080-9

Abatacept modulates human dendritic cell-stimulated T-cell proliferation and effector function independent of IDO induction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0080-9

Decreased circulating CD28-negative T cells in patients with rheumatoid arthritis treated with abatacept are correlated with clinical response.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0080-9

Abatacept (CTLA-4IG) treatment reduces the migratory capacity of monocytes in patients with rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0080-9

Mode of action of abatacept in rheumatoid arthritis patients having failed tumour necrosis factor blockade: a histological, gene expression and dynamic magnetic resonance imaging pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0080-9

Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept: twelve-month results of a phase iib, double-blind, randomized, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0080-9

Model-based determination of abatacept exposure in support of the recommended dose for Japanese rheumatoid arthritis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0080-9

Safety and efficacy of the selective costimulation modulator abatacept in patients with rheumatoid arthritis receiving background methotrexate: a 5-year extended phase IIB study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0080-9

Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: a randomized trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0080-9

Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multi-centre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0080-9

Clinical efficacy and safety of abatacept in methotrexate-naive patients with early rheumatoid arthritis and poor prognostic factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0080-9

The 6-month safety and efficacy of abatacept in patients with rheumatoid arthritis who underwent a washout after anti-tumour necrosis factor therapy or were directly switched to abatacept: the ARRIVE trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0080-9

Positivity for anti-cyclic citrullinated peptide is associated with a better response to abatacept: data from the 'Orencia and Rheumatoid Arthritis' registry

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0080-9

Sustained disease remission and inhibition of radiographic progression in methotrexate-naive patients with rheumatoid arthritis and poor prognostic factors treated with abatacept: 2-year outcomes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0080-9

Abatacept inhibits progression of structural damage in rheumatoid arthritis: results from the long-term extension of the AIM trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0080-9

Long-term safety, efficacy and inhibition of radiographic progression with abatacept treatment in patients with rheumatoid arthritis and an inadequate response to methotrexate: 3-year results from the AIM trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0080-9

Clinical response and tolerability to abatacept in patients with rheumatoid arthritis previously treated with infliximab or abatacept: open-label extension of the ATTEST Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0080-9

Abatacept improves both the physical and mental health of patients with rheumatoid arthritis who have inadequate response to methotrexate treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0080-9

Investigation into the impact of abatacept on sleep quality in patients with rheumatoid arthritis, and the validity of the MOS-Sleep questionnaire Sleep Disturbance Scale

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0080-9

Decreased external home help use with improved clinical status in rheumatoid arthritis: an exploratory analysis of the Abatacept in Inadequate responders to Methotrexate (AIM) trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0080-9

Efficacy and safety of the selective co-stimulation modulator abatacept following 2 years of treatment in patients with rheumatoid arthritis and an inadequate response to anti-tumour necrosis factor therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0080-9

Longterm safety and efficacy of abatacept through 5 years of treatment in patients with rheumatoid arthritis and an inadequate response to tumor necrosis factor inhibitor therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0080-9

Improved health-related quality of life for rheumatoid arthritis patients treated with abatacept who have inadequate response to anti-TNF therapy in a double-blind, placebo-controlled, multicentre randomized clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0080-9

Improvements in participation in usual daily activities in patients with rheumatoid arthritis treated with abatacept

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0080-9

Subcutaneous abatacept versus intravenous abatacept: a phase IIIb noninferiority study in patients with an inadequate response to methotrexate.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0080-9

Abatacept in subjects who switch from intravenous to subcutaneous therapy: results from the phase IIIb ATTUNE study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0080-9

Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: findings of a phase IIIb, multinational, prospective, randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0080-9

Evaluation of abatacept administered subcutaneously in adults with active rheumatoid arthritis: impact of withdrawal and reintroduction on immunogenicity, efficacy and safety (phase Iiib ALLOW study).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0080-9

Immunogenicity, safety, and efficacy of abatacept administered subcutaneously with or without background methotrexate in patients with rheumatoid arthritis: results from a phase III, international, multicenter, parallel-arm, open-label study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0080-9

Abatacept in children with juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled withdrawal trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0080-9

Long-term safety and efficacy of abatacept in children with juvenile idiopathic arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0080-9

Abatacept improves health-related quality of life, pain, sleep quality, and daily participation in subjects with juvenile idiopathic arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0080-9

Safety of the selective costimulation modulator abatacept in rheumatoid arthritis patients receiving background biologic and nonbiologic disease-modifying antirheumatic drugs: A one-year randomized, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0080-9

Infections requiring hospitalization in the abatacept clinical development program: an epidemiological assessment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0080-9

Malignancies in the rheumatoid arthritis abatacept clinical development programme: an epidemiological assessment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0080-9

A meta-analysis of the incidence of malignancy in adult patients with rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0080-9

Abatacept with methotrexate versus other biologic agents in treatment of patients with active rheumatoid arthritis despite methotrexate: a network meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0080-9

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0080-9

Abatacept use in rheumatoid arthritis: evidence review and recommendations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0080-9

The efficacy and safety of abatacept in rheumatoid arthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0080-9

Selective costimulation modulation using abatacept in patients with active rheumatoid arthritis while receiving etanercept: a randomised clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0080-9

Economic aspects of treatment options in rheumatoid arthritis: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0080-9

Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a tumour necrosis factor inhibitor: a systematic review and economic evaluation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0080-9

Costimulatory blockade in patients with rheumatoid arthritis: a pilot, dose-finding, double-blind, placebo-controlled clinical trial evaluating CTLA-4Ig and LEA29Y eighty-five days after the first infusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0080-9

Phase II dose-response study of abatacept in Japanese patients with active rheumatoid arthritis with an inadequate response to methotrexate.

21 January 2018

2 references

https://api.crossref.org/works/10.1007%2FS40265-013-0080-9

21 January 2018

12 December 2020

Abatacept in the treatment of polyarticular JIA: development, clinical utility, and place in therapy

1 reference

12 December 2020

Safety of abatacept administered intravenously in treatment of rheumatoid arthritis: integrated analyses of up to 8 years of treatment from the abatacept clinical trial program

1 reference

12 December 2020

Tolerability and efficacy of abatacept in Japanese patients with rheumatoid arthritis: a phase I study

1 reference

12 December 2020

The risk of hospitalized infection in patients with rheumatoid arthritis.

1 reference

12 December 2020

Abatacept in difficult-to-treat juvenile idiopathic arthritis.

1 reference

12 December 2020

Abatacept binds to the Fc receptor CD64 but does not mediate complement-dependent cytotoxicity or antibody-dependent cellular cytotoxicity

1 reference

12 December 2020

Results of a two-year followup study of patients with rheumatoid arthritis who received a combination of abatacept and methotrexate

1 reference

12 December 2020

Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig

1 reference

12 December 2020

Impact of intravenous abatacept on synovitis, osteitis and structural damage in patients with rheumatoid arthritis and an inadequate response to methotrexate: the ASSET randomised controlled trial

1 reference

12 December 2020

Reduction of inflammatory biomarker response by abatacept in treatment of rheumatoid arthritis.

1 reference

12 December 2020

Modeling and simulation of abatacept exposure and interleukin-6 response in support of recommended doses for rheumatoid arthritis

1 reference

12 December 2020

Abatacept plus methotrexate provides incremental clinical benefits versus methotrexate alone in methotrexate-naive patients with early rheumatoid arthritis who achieve radiographic nonprogression

1 reference

12 December 2020

Use of abatacept in rheumatoid arthritis

1 reference

12 December 2020

Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition

1 reference

12 December 2020

10.1007/S40265-013-0080-9

Identifiers

DOI

1 reference

Dimensions Publication ID

29 August 2017

1001475360

0 references

Fatcat ID

release_yip2ym5aqzeo3osi37ytkhdzna

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/yip2ym5aqzeo3osi37ytkhdzna

24 November 2022

mapped directly with Wikidata item

1 reference